Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EPS (Weighted Average and Diluted) (2019 - 2025)

Bioadaptives' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.07 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 75.0% to -$0.07 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.11, a 450.0% decrease, with the full-year FY2025 number at -$0.15, down 36.36% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.07 in Q4 2025 for Bioadaptives, down from -$0.04 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for BDPT hit a ceiling of $0.06 in Q2 2024 and a floor of -$0.07 in Q4 2025.